Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series
Yuan Zhang,1,* Zheyu Fang,1,* Yaping Liu,2,* Bingbing Wan,1 Qiaoyi Zhang,1 Xi Qu,1 Shengli Pan,1 Yu Zhang,1 Yilin Dai,1 Shiyin Yang,1 Jia Li,1 Xu Zhang1 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-04-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efgartigimod-followed-by-telitacicept-in-adult-generalized-myasthenia--peer-reviewed-fulltext-article-JIR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849702140801449984 |
|---|---|
| author | Zhang Y Fang Z Liu Y Wan B Zhang Q Qu X Pan S Zhang Y Dai Y Yang S Li J Zhang X |
| author_facet | Zhang Y Fang Z Liu Y Wan B Zhang Q Qu X Pan S Zhang Y Dai Y Yang S Li J Zhang X |
| author_sort | Zhang Y |
| collection | DOAJ |
| description | Yuan Zhang,1,* Zheyu Fang,1,* Yaping Liu,2,* Bingbing Wan,1 Qiaoyi Zhang,1 Xi Qu,1 Shengli Pan,1 Yu Zhang,1 Yilin Dai,1 Shiyin Yang,1 Jia Li,1 Xu Zhang1 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2Department of Neurology, Lianshui People’s Hospital, Huai’an, Jiangsu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jia Li, Email lijia@wzhospital.cn Xu Zhang, Email drzhangxu@live.cnBackground: The emergence of biologics for the treatment of generalized myasthenia gravis (gMG) has increased therapeutic options, but evidence on their flexible use remains limited.Purpose: This study retrospectively analyzed gMG patients treated with efgartigimod followed by telitacicept.Methods: A retrospective analysis was conducted on gMG patients treated with efgartigimod followed by telitacicept. Outcomes included changes in Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores from baseline to weeks 13 and 28, Minimal Manifestation Status (MMS), corticosteroid-sparing potential, safety, and serological markers.Results: Among seven patients included for efficacy evaluation, the baseline QMG and MG-ADL scores were 12.4± 4.3 and 7.1± 3.6, respectively. These scores decreased by 8.4± 3.9 and 5.7± 4.2 at week 13 and further decreased by 8.7± 3.2 and 6.8± 3.4 by week 28 (both P < 0.001). Six patients (86%) achieved Minimal Manifestation Status (MMS), with a median time to achieve MMS being 9 weeks. The average prednisone dosage was significantly reduced from 51.43± 14.64 mg at baseline to 5.71± 1.89 mg by week 28 (P < 0.05). Common adverse events included mild injection site reactions (n=2) and upper respiratory infections (n=2), with no serious events reported. IgM and IgA levels significantly declined by week 17 (P < 0.05), while BAFF levels increased significantly following telitacicept treatment by week 21 (P < 0.05).Conclusion: This regimen demonstrated favorable efficacy and safety, suggesting its potential as an effective option for gMG management.Keywords: generalized myasthenia gravis, efgartigimod, telitacicept, sequential therapy, targeted therapy |
| format | Article |
| id | doaj-art-e19a91a3d29c4c6d921a374fcda354dd |
| institution | DOAJ |
| issn | 1178-7031 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj-art-e19a91a3d29c4c6d921a374fcda354dd2025-08-20T03:17:44ZengDove Medical PressJournal of Inflammation Research1178-70312025-04-01Volume 1848314842101906Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case SeriesZhang YFang ZLiu YWan BZhang QQu XPan SZhang YDai YYang SLi JZhang XYuan Zhang,1,* Zheyu Fang,1,* Yaping Liu,2,* Bingbing Wan,1 Qiaoyi Zhang,1 Xi Qu,1 Shengli Pan,1 Yu Zhang,1 Yilin Dai,1 Shiyin Yang,1 Jia Li,1 Xu Zhang1 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2Department of Neurology, Lianshui People’s Hospital, Huai’an, Jiangsu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jia Li, Email lijia@wzhospital.cn Xu Zhang, Email drzhangxu@live.cnBackground: The emergence of biologics for the treatment of generalized myasthenia gravis (gMG) has increased therapeutic options, but evidence on their flexible use remains limited.Purpose: This study retrospectively analyzed gMG patients treated with efgartigimod followed by telitacicept.Methods: A retrospective analysis was conducted on gMG patients treated with efgartigimod followed by telitacicept. Outcomes included changes in Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores from baseline to weeks 13 and 28, Minimal Manifestation Status (MMS), corticosteroid-sparing potential, safety, and serological markers.Results: Among seven patients included for efficacy evaluation, the baseline QMG and MG-ADL scores were 12.4± 4.3 and 7.1± 3.6, respectively. These scores decreased by 8.4± 3.9 and 5.7± 4.2 at week 13 and further decreased by 8.7± 3.2 and 6.8± 3.4 by week 28 (both P < 0.001). Six patients (86%) achieved Minimal Manifestation Status (MMS), with a median time to achieve MMS being 9 weeks. The average prednisone dosage was significantly reduced from 51.43± 14.64 mg at baseline to 5.71± 1.89 mg by week 28 (P < 0.05). Common adverse events included mild injection site reactions (n=2) and upper respiratory infections (n=2), with no serious events reported. IgM and IgA levels significantly declined by week 17 (P < 0.05), while BAFF levels increased significantly following telitacicept treatment by week 21 (P < 0.05).Conclusion: This regimen demonstrated favorable efficacy and safety, suggesting its potential as an effective option for gMG management.Keywords: generalized myasthenia gravis, efgartigimod, telitacicept, sequential therapy, targeted therapyhttps://www.dovepress.com/efgartigimod-followed-by-telitacicept-in-adult-generalized-myasthenia--peer-reviewed-fulltext-article-JIRgeneralized myasthenia gravisefgartigimodtelitaciceptsequential therapytargeted therapy |
| spellingShingle | Zhang Y Fang Z Liu Y Wan B Zhang Q Qu X Pan S Zhang Y Dai Y Yang S Li J Zhang X Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series Journal of Inflammation Research generalized myasthenia gravis efgartigimod telitacicept sequential therapy targeted therapy |
| title | Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series |
| title_full | Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series |
| title_fullStr | Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series |
| title_full_unstemmed | Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series |
| title_short | Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series |
| title_sort | efgartigimod followed by telitacicept in adult generalized myasthenia gravis a retrospective case series |
| topic | generalized myasthenia gravis efgartigimod telitacicept sequential therapy targeted therapy |
| url | https://www.dovepress.com/efgartigimod-followed-by-telitacicept-in-adult-generalized-myasthenia--peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT zhangy efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT fangz efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT liuy efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT wanb efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT zhangq efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT qux efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT pans efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT zhangy efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT daiy efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT yangs efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT lij efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries AT zhangx efgartigimodfollowedbytelitaciceptinadultgeneralizedmyastheniagravisaretrospectivecaseseries |